Autopsy report · NCT03674242
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
Cause of deathFunding or business
“sponsor decision”
Life of this trial
- Registered 9 months before it started.
- Ran for about 2 years 10 months before it stopped.
- 27 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- ERYtech Pharma
- Sponsor type
- Industry
- Conditions
- Triple Negative Breast Cancer
- Interventions
- eryaspase (L-asparaginase encapsulated in red blood cells); Gemcitabine; Carboplatin
- Participants
- 27
- Sites
- 16
- Countries
- Belgium, Hungary, Spain
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.